mDAS

Trial question

What is the role of mobile health diabetes support intervention in patients with T2DM?

Study design

Multi-center

Open label

RCT

Population

Characteristics of study participants

70.0% female

30.0% male

N = 221

221 patients (154 female, 67 male)

Inclusion criteria: adult patients with T2DM with HbA1c ≥ 8%

Key exclusion criteria: dementia; pregnancy; history of receiving or planning to receive gastric bypass or transplant surgery; unable to send or read text messages on mobile phone

Interventions

N=109 mobile health diabetes support intervention (12 month diabetes management support from a pharmacist via video conference and a health coach via home visits, telephone calls, and text messages)

N=112 waiting list usual care (routine diabetes care through primary care clinician for 12 months followed by 12 month intervention)

Primary outcome

Improvement in mean hemoglobin A1c at 12 months

0.79

0.24

0.8 %

0.6 %

0.4 %

0.2 %

0.0 %

Mobile health diabetes support intervention

Waiting list usual care

Significant increase ▲

NNT = 181

Significant increase in improvement in mean HbA1c at 12 months (0.79% vs. 0.24%; MD 0.62, 95% CI 0.19 to 1.04)

Secondary outcomes

No significant difference in mean SBP at 12 months (131.16 mmHg vs. 135.03 mmHg; MD -3.88, 95% CI -8.08 to 0.32)

No significant difference in mean total cholesterol at 12 months (158.35 mg/dL vs. 165.62 mg/dL; MD -7.27, 95% CI -19.34 to 4.8)

No significant difference in mean diabetes distress (2.07 vs. 2.37 ; MD -0.29, 95% CI -0.63 to 0.05)

Conclusion

In adult patients with T2DM with HbA1c ≥ 8%, mobile health diabetes support intervention was superior to waiting list usual care with respect to improvement in mean HbA1c at 12 months.

Reference

Ben S Gerber, Alana Biggers, Jessica J Tilton et al. Mobile Health Intervention in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA Netw Open. 2023 Sep 5;6(9):e2333629.

Open reference URL

Create free account